Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.10
- Piotroski Score 6.00
- Grade Buy
- Symbol (LNTH)
- Company Lantheus Holdings, Inc.
- Price $86.48
- Changes Percentage (8.88%)
- Change $7.05
- Day Low $82.14
- Day High $86.60
- Year High $126.89
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $145.00
- High Stock Price Target $175.00
- Low Stock Price Target $120.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $6.56
- Trailing P/E Ratio 12.18
- Forward P/E Ratio 12.18
- P/E Growth 12.18
- Net Income $326.66 M
Income Statement
Quarterly
Annual
Latest News of LNTH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Lantheus Holdings Inc (LNTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
PYLARIFY's Q3 revenue growth of 20% and projected mid-20% growth in 2024 were explained by Paul Blanchfield. Factors affecting revenue included seasonality, strategic partnerships, and product availab...
By Yahoo! Finance | 2 weeks ago -
Lantheus Holdings (LNTH) Achieves 22.5% Revenue Growth in Q2 2024
The article discusses Lantheus Holdings, Inc. in comparison to other top medical stocks favored by hedge funds....
By Yahoo! Finance | 2 weeks ago -
Is Lantheus Holdings (LNTH)The Most Undervalued Quality Stock To Buy According To Analysts?
A list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts was compiled, focusing on Lantheus Holdings. Amid market challenges, quality stocks offer opportunities for investors, esp...
By Yahoo! Finance | 1 month ago
